What is Generate Biomedicines, Inc.'s (GENB) StockRank?

MoatMap's StockRank for Generate Biomedicines, Inc. (GENB) is 7/100, with a Strong Sell signal. This is a composite score combining Quality (19), Value (24), and Momentum (33) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Generate Biomedicines, Inc. have an economic moat?

Generate Biomedicines, Inc. (GENB) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Generate Biomedicines, Inc. a buy, hold, or sell?

MoatMap's current signal for Generate Biomedicines, Inc. (GENB) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Generate Biomedicines, Inc. in?

Generate Biomedicines, Inc. (GENB) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GENB

Strong SellSinker

Generate Biomedicines, Inc. · Healthcare · United States · $2.0B · Avg Vol: $18M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

—

D/E

0.1x

Dividend %

—

COMPANY DESCRIPTION

Generate Biomedicines, Inc. is a biotechnology company pioneering a machine learning-powered generative biology platform to create novel protein therapeutics. It leverages AI and computational biology to design and optimize drugs from scratch, accelerating discovery and expanding the druggable target space. This is a cutting-edge biotech firm at the forefront of AI-driven drug discovery, aiming to revolutionize therapeutic development.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	20.5M	31.9M	26.5M	29.7M	23.8M	-13.6%
EPS	-2.09	-2.18	-2.09	-2.30	-2.28	—
Shares	127.5M	127.5M	128.4M	—	—	—
Debt	77.0M	68.5M	62.6M	—	—	—
Equity	-434.5M	-616.0M	—	—	—	—
Op CF	-117.8M	-200.6M	-237.0M	—	—	—
Inv CF	-57.7M	116.8M	—	—	—	—
Fin CF	91.3M	28.1M	—	—	—	—

Loading 1Y...

PRICE (1Y)+18.7%

SMA 50SMA 200

$15.52

RSI (14)

44.2

SCORE BREAKDOWN

Quality

ROIC

-89.4%7.8

ROE

—N/A

GP/Assets

-64.8%0.6

Op. Margin

-1134.2%6.7

FCF/Assets

-61.8%5.0

Piotroski

321.9

Int. Cover

-50.0x5.9

D/E Ratio

0.14x57.6

Current Ratio

8.30x84.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-6.8x25.0

P/FCF

—N/A

P/B

4.6x31.5

P/S

79.4x7.5

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

14%77.4

SMA 50/200

—N/A

EPS Rev 4W

-10.4%8.3

EPS Rev 12W

-10.4%12.1

EPS Improve

-9%18.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.0B

P/E (Forward)

-7.2x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GENB are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
GENB	Generate Biomedicines, Inc.(you)	$2.0B	7	Strong Sell
NTLA	Intellia Therapeutics, Inc.	$1.8B	7	Strong Sell
SNDX	Syndax Pharmaceuticals, Inc.	$1.7B	7	Strong Sell
BRVE	Braveheart Bio, Inc.	$1.9B	11	Strong Sell
VERA	Vera Therapeutics, Inc.	$2.5B	6	Strong Sell
KARD	Kardigan, Inc.	$1.9B	11	Strong Sell
COAG	Hemab Therapeutics Holdings, Inc.	$2.1B	11	Strong Sell
MAZE	Maze Therapeutics, Inc.	$1.5B	7	Strong Sell
KLRA	Kailera Therapeutics, Inc.	$2.1B	11	Strong Sell
TRAX	First Tracks Biotherapeutics, Inc.	$1.5B	6	Strong Sell

Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%

Generate Biomedicines, Inc. (GENB): Stock Score Summary

Generate Biomedicines, Inc. (GENB) has a MoatMap StockRank of 7/100 based on Quality (19/100), Value (24/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$15.52
Market Cap	$2.0B
P/E (Forward)	-7.19
Price/Book	4.61
Return on Invested Capital	-89.4%
Debt/Equity	0.14x
Operating Margin	-1134.2%
Revenue Growth	-37.7%
Free Cash Flow	$-204M

Generate Biomedicines, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Generate Biomedicines, Inc.’s (GENB) StockRank?: MoatMap’s StockRank for Generate Biomedicines, Inc. (GENB) is 7/100, with a Strong Sell signal. It is a composite of Quality (19), Value (24), and Momentum (33) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Generate Biomedicines, Inc. have an economic moat?: Generate Biomedicines, Inc. (GENB) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Generate Biomedicines, Inc. a buy, hold, or sell?: MoatMap’s current signal for Generate Biomedicines, Inc. (GENB) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Generate Biomedicines, Inc. in?: Generate Biomedicines, Inc. (GENB) operates in the Healthcare sector, specifically the Biotechnology industry (United States).